The comprehensive evaluation across RAGE expression, cell viability, and apoptosis assays supports Paliperidone’s multifaceted potential as a therapeutic agent targeting cancer cells, particularly in contexts where HMGB1-mediated pathways are implicated. This evidence concerns the gene HMGB1 and cancer.